Asset / Drug

Dabogratinib

Drug and asset intelligence for Dabogratinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Tyra Biosciences, Inc →

Recent signals(1)

ClinicalJuly 5, 2026

Tyra Biosciences initiates Phase 2A/B trial of Dabogratinib for Low Grade Upper Tract Urothelial Carcinoma

Tyra Biosciences is conducting Phase 2A/B trial to evaluate the efficacy and safety of Dabogratinib in patients with Low Grade Upper Tract Urothelial Carcinoma.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Tyra Biosciences, Inc — Dabogratinib

Monitor trial results and any announcements regarding efficacy and safety outcomes.

July 5, 2026 · N/A

Indications

Urothelial Carcinoma →

Therapeutic areas

Oncology →

Oncology · Urothelial Carcinoma →

Urothelial Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.